CSF3 and neutropenia: The use of G-CSF as primary prophylaxis was high (84.8% in mTNBC; 73.9% in HR+/HER2− mBC), with a lower prevalence of neutropenia of any grade (27.3% in mTNBC and 8.7% in HR+/HER2− mBC) than that reported in other mTNBC studies, where the prevalence ranged from 55% to 66.7%, depending on the study and the rate of G-CSF use [8,12,13,15].